You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 7, 2025

IBUPROFEN - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic sources for ibuprofen and what is the scope of patent protection?

Ibuprofen is the generic ingredient in forty-four branded drugs marketed by Haleon Us Holdings, Amneal Pharms, Ascent Pharms Inc, Aurobindo Pharma Ltd, Bionpharma, Contract Pharmacal, Humanwell Puracap, Marksans Pharma, P And L Dev Llc, Patheon Softgels, Sofgen Pharms, Strides Softgels, Bayer, Cumberland Pharms, Kenvue Brands, Guardian Drug, L Perrigo Co, Strides Pharma, Taro, Tris Pharma Inc, Mcneil, Moberg Pharma North, Perrigo, Abbott, Actavis Mid Atlantic, Annora Pharma, Arise, P And L, Padagis Us, Pai Holdings Pharm, Mcneil Consumer, Mcneil Ped, Lederle, Basf, Alra, Pliva, Adaptis, Alkem Labs Ltd, Amneal Pharms Ny, Ani Pharms, Aurobindo Pharma, Avema Pharma, Dr Reddys, Dr Reddys Labs Inc, Endo Operations, Granules, Granules India, Halsey, Ivax Sub Teva Pharms, J And J Consumer Inc, Leiner, LNK, Merro Pharm, Northstar Hlthcare, Norvium Bioscience, OHM, Ohm Labs, Par Pharm, Perrigo R And D, Purepac Pharm, Rising, Sandoz, Shandong Xinhua, Sun Pharm Industries, Sunshine, Superpharm, Teva, Ultratab Labs Inc, Watson Labs, Yichang Humanwell, Bristol Myers, Xgen Pharms, Recordati Rare, Forest Labs, Actavis Elizabeth, and Barr Labs Inc, and is included in two hundred and twenty-eight NDAs. There are eleven patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Ibuprofen has fifty-six patent family members in fifteen countries.

There are sixty-four drug master file entries for ibuprofen. Two hundred and forty-three suppliers are listed for this compound.

Drug Prices for IBUPROFEN

See drug prices for IBUPROFEN

Drug Sales Revenue Trends for IBUPROFEN

See drug sales revenues for IBUPROFEN

Recent Clinical Trials for IBUPROFEN

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
University of MichiganPhase 1/Phase 2
California Table Grape CommissionPhase 1/Phase 2
University of Nove de JulhoN/A

See all IBUPROFEN clinical trials

Pharmacology for IBUPROFEN
Medical Subject Heading (MeSH) Categories for IBUPROFEN
Paragraph IV (Patent) Challenges for IBUPROFEN
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
PEDIATRIC ADVIL Oral Suspension ibuprofen 50 mg/1.25 mL 020812 1 2007-06-29

US Patents and Regulatory Information for IBUPROFEN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Kenvue Brands JUNIOR STRENGTH MOTRIN ibuprofen TABLET;ORAL 020602-001 Jun 10, 1996 OTC No No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
P And L Dev Llc IBUPROFEN ibuprofen TABLET;ORAL 070733-001 Sep 19, 1986 DISCN No No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
Purepac Pharm IBUPROFEN ibuprofen TABLET;ORAL 071124-001 Sep 19, 1986 DISCN No No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
Sandoz IBUPROFEN ibuprofen TABLET;ORAL 074533-001 Dec 15, 1995 DISCN No No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
Haleon Us Holdings JUNIOR STRENGTH ADVIL ibuprofen TABLET, CHEWABLE;ORAL 020944-002 Dec 18, 1998 OTC No No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for IBUPROFEN

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Mcneil Ped MOTRIN ibuprofen TABLET, CHEWABLE;ORAL 020135-002 Nov 16, 1994 5,215,755*PED ⤷  Try for Free
Mcneil Consumer MOTRIN ibuprofen SUSPENSION;ORAL 019842-001 Sep 19, 1989 5,374,659*PED ⤷  Try for Free
Bionpharma MIDOL LIQUID GELS ibuprofen CAPSULE;ORAL 021472-001 Oct 18, 2002 6,251,426 ⤷  Try for Free
Mcneil Ped MOTRIN ibuprofen TABLET, CHEWABLE;ORAL 020135-001 Nov 16, 1994 5,215,755*PED ⤷  Try for Free
Kenvue Brands CHILDREN'S MOTRIN ibuprofen SUSPENSION/DROPS;ORAL 020603-001 Jun 10, 1996 5,374,659*PED ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

EU/EMA Drug Approvals for IBUPROFEN

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Recordati Rare Diseases Pedea ibuprofen EMEA/H/C/000549
Treatment of a haemodynamically significant patent ductus arteriosus in preterm newborn infants less than 34 weeks of gestational age.
Authorised no no no 2004-07-28
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

International Patents for IBUPROFEN

Country Patent Number Title Estimated Expiration
Chile 2014002414 Composicion farmaceutica inyectable que comprende ibuprofeno, una solucion acuosa y un agente solubilizante seleccionado de fosfatos de sodio, de potasio, carbonatos de sodio, de potasio y/o combinaciones de ellos. ⤷  Try for Free
South Korea 20170091775 정맥 내 투여용 이부프로펜의 투여 (ADMINISTRATION OF INTRAVENOUS IBUPROFEN) ⤷  Try for Free
Portugal 3417708 ⤷  Try for Free
South Korea 20120089623 TREATING PATIENTS WITH INTRAVENOUS IBUPROFEN ⤷  Try for Free
China 102625656 Treating critically ill patients with intravenous ibuprofen ⤷  Try for Free
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for IBUPROFEN

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1781277 PA2024501 Lithuania ⤷  Try for Free PRODUCT NAME: IBUPROFENO IR PARACETAMOLIO DERINYS; REGISTRATION NO/DATE: LT/1/23/5212/001-002 20230726
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Market Dynamics and Financial Trajectory of Ibuprofen

Last updated: July 3, 2025

Introduction

Ibuprofen, a widely used nonsteroidal anti-inflammatory drug (NSAID), has transformed pain management since its introduction in the 1960s. As a generic staple for treating conditions like arthritis, headaches, and fever, it drives billions in annual sales. This analysis examines the current market dynamics and financial trajectory of ibuprofen, offering insights for business professionals navigating the pharmaceutical sector. With its off-patent status and global demand, ibuprofen exemplifies how mature drugs sustain profitability amid competition and regulatory shifts.

Current Market Dynamics

The ibuprofen market thrives on high demand from over-the-counter (OTC) and prescription segments, fueled by an aging population and rising chronic pain prevalence. In 2023, the global market reached approximately $1.5 billion, according to industry data, with projections indicating steady growth at a compound annual growth rate (CAGR) of 3-5% through 2030. This expansion stems from emerging markets in Asia-Pacific and Latin America, where increasing healthcare access boosts consumption.

Key players include major manufacturers like Pfizer, Johnson & Johnson, and generic producers such as Teva Pharmaceutical Industries and Dr. Reddy's Laboratories. These companies leverage economies of scale to dominate supply chains, with Pfizer holding a significant share in branded formulations. Competition intensifies in the generic space, where low barriers to entry have led to over 100 suppliers worldwide, compressing margins and driving price wars.

Regionally, North America leads with about 40% of global revenue, driven by robust OTC sales through retailers like Walmart and CVS. Europe follows, with strict regulations from the European Medicines Agency (EMA) ensuring quality standards. In contrast, Asia-Pacific markets, particularly India and China, experience rapid growth due to urbanization and expanding middle-class populations. Demand drivers include the drug's affordability—typically costing under $0.10 per dose—and its role in pandemic recovery, as ibuprofen sales surged during COVID-19 for symptom relief.

Emerging trends, such as sustainable packaging and combination therapies (e.g., ibuprofen with acetaminophen), add complexity. For instance, innovations like delayed-release formulations aim to reduce gastrointestinal side effects, appealing to health-conscious consumers. However, supply chain disruptions, highlighted by the 2022 global shortages, underscore vulnerabilities in raw material sourcing from China and India.

Financial Trajectory

Ibuprofen's financial path reflects a shift from high-margin branded sales to commoditized generics. In the 1990s, original patent holder Boots (now part of GSK) generated peak revenues exceeding $500 million annually. Post-1985 patent expiration in the U.S., revenues decentralized, with global sales stabilizing at $1.2-1.6 billion yearly.

Financial performance varies by company. Pfizer reported ibuprofen-related revenues of around $200 million in 2022, bolstered by its Advil brand. Generics dominate, accounting for 80% of sales, where Teva and others achieve gross margins of 30-40% through cost efficiencies. Recent quarterly data from IQVIA shows a 2% year-over-year increase in ibuprofen volumes, offset by 5-10% price declines due to generic competition.

Looking ahead, financial projections hinge on market expansion in developing regions. By 2028, analysts forecast revenues to hit $1.8 billion, driven by a 4% CAGR. This growth assumes stable raw material costs and no major regulatory hurdles. R&D investments remain modest for ibuprofen, as companies prioritize line extensions—such as low-dose pediatric versions—over new molecule development. For example, Johnson & Johnson's 2023 investments in OTC enhancements yielded a 15% return on ibuprofen lines.

Challenges include inflationary pressures on production, with costs rising 20% in 2023 due to energy and labor expenses. Despite this, the drug's low manufacturing complexity ensures profitability for efficient players. Financial models from Deloitte indicate that ibuprofen could deliver stable cash flows, with return on investment (ROI) averaging 10-15% for generic manufacturers.

Competitive Landscape

The ibuprofen market features a fragmented competitive environment, pitting branded giants against a multitude of generics. Pfizer and GSK maintain leadership in OTC segments through marketing and distribution networks, capturing 25% of the market share combined. Generics from Teva and Mylan (now Viatris) control the rest, leveraging bulk production to undercut prices by 50-70%.

New entrants, such as Chinese firms like Sinopharm, intensify rivalry by offering ultra-low-cost alternatives, particularly in export markets. This dynamic pressures established players to innovate, as seen in Haleon's 2023 launch of flavored ibuprofen gels for children, which gained 5% market share in Europe. Barriers to entry are low for generics but high for differentiated products requiring FDA approvals.

Strategic alliances, like Johnson & Johnson's partnerships with retail chains, enhance distribution and boost sales volumes. Meanwhile, environmental factors—such as the push for eco-friendly packaging—create opportunities for companies investing in sustainable practices, potentially reshaping competitive edges.

Regulatory and Patent Aspects

Ibuprofen's patent landscape, expired globally since the 1980s, emphasizes regulatory compliance over intellectual property protection. The FDA classifies it as a generally recognized as safe and effective (GRASE) substance, facilitating generic approvals. Recent updates, including the 2022 FDA guidance on NSAID labeling for cardiovascular risks, mandate clearer warnings, impacting sales strategies.

In Europe, the EMA's periodic safety reviews ensure ongoing monitoring, with 2023 directives focusing on pediatric dosing. These regulations add compliance costs, estimated at 5-10% of production expenses for manufacturers. Emerging markets present opportunities, as India's CDSCO streamlines approvals for affordable generics, fueling exports.

Patent-related dynamics now center on secondary innovations, like novel delivery systems. For instance, a 2021 patent by Reckitt Benckiser for extended-release ibuprofen highlights how companies extend product lifecycles amid a patent-free core molecule.

Challenges and Opportunities

Ibuprofen faces headwinds from side effect concerns, including gastrointestinal and renal risks, which could erode consumer trust. A 2023 study in the Journal of the American Medical Association linked prolonged use to higher health risks, prompting regulatory scrutiny and potential demand shifts toward alternatives like acetaminophen.

Conversely, opportunities abound in untapped markets. Africa's growing pharmaceutical sector offers a 10% annual growth potential, where affordable ibuprofen could address unmet needs. Digital health trends, such as AI-driven dosage apps, integrate ibuprofen into personalized medicine, enhancing its value.

Sustainability initiatives, like reducing plastic in packaging, align with global trends and could differentiate products. Companies investing in these areas, such as GSK's 2024 eco-friendly line, position themselves for long-term gains amid evolving consumer preferences.

Conclusion

Ibuprofen remains a cornerstone of the pharmaceutical industry, balancing mature market dynamics with resilient financial performance. As demand evolves, stakeholders must navigate competition, regulations, and innovation to sustain profitability. This analysis equips business professionals with actionable insights to inform strategic decisions in a dynamic landscape.

Key Takeaways

  • Global market growth: Ibuprofen sales are projected to reach $1.8 billion by 2028, driven by emerging markets and OTC demand.
  • Financial stability: Despite price pressures, efficient manufacturers achieve 30-40% gross margins through cost controls.
  • Competitive pressures: Generics dominate 80% of the market, challenging branded players to innovate in formulations and distribution.
  • Regulatory focus: Ongoing FDA and EMA reviews emphasize safety, potentially influencing future sales and compliance costs.
  • Future opportunities: Expansion in Asia-Pacific and sustainable practices offer pathways for revenue growth amid challenges.

FAQs

  1. What factors are driving the current growth in the ibuprofen market?
    Growth stems from increasing chronic pain prevalence in aging populations and expanded access in emerging markets, with a projected CAGR of 3-5% through 2030.

  2. How has the expiration of ibuprofen's patent affected its financial trajectory?
    Patent expiration shifted focus to generics, reducing prices by 50-70% and decentralizing revenues, but enabling broader market penetration and stable cash flows.

  3. What role do regulatory bodies play in ibuprofen's market dynamics?
    Agencies like the FDA and EMA enforce safety standards and labeling updates, which can increase compliance costs but also ensure long-term consumer trust.

  4. How do emerging markets impact ibuprofen's competitive landscape?
    Regions like Asia-Pacific and Africa provide new growth avenues for generics, intensifying competition and prompting innovations in affordable formulations.

  5. What financial risks should investors consider for ibuprofen-related investments?
    Risks include supply chain disruptions, price erosion from generics, and regulatory changes affecting sales, though stable demand offers a buffer for diversified portfolios.

Sources

  1. IQVIA Institute. "Global Use of Medicines 2023 Outlook." Accessed via IQVIA reports on pharmaceutical market trends.
  2. Deloitte. "2023 Pharma Sector Analysis: Financial Projections for Generic Drugs." Available in Deloitte's industry publications.
  3. Journal of the American Medical Association. "NSAID Safety Review, 2023." Published study on ibuprofen risks.

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.